home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407a.zip
/
M9470050.TXT
< prev
next >
Wrap
Text File
|
1994-07-02
|
2KB
|
38 lines
Document 0050
DOCN M9470050
TI [Primary and secondary prevention of Pneumocystis carinii pneumonia with
pentamidine aerosol. Effectiveness, side effects and incidence of
extrapulmonary Pneumocystis carinii manifestations]
DT 9409
AU Stoehr A; Plettenberg A; Albrecht H; Stellbrink HJ; Meigel W; Begemann
F; Allgemeines Krankenhaus St. Georg, Interdisziplinare; HIV-Ambulanz
Hamburg.
SO Med Klin. 1994 Mar 15;89(3):132-5. Unique Identifier : AIDSLINE
MED/94254759
AB BACKGROUND: We report on a retrospective study in 544 HIV-positive
patients, (42 women, 502 men, mean age 35 years) showing CD4 lymphocyte
counts below 200 c/mcl or after their cure of Pneumocystis carinii
pneumonia, who received 300 mg pentamidine aerosol as prophylaxis
against Pneumocystis carinii pneumonia every four week. PATIENTS AND
METHODS: 277 patients were asymptomatic, 120 in the AIDS related complex
stage (ARC) and 147 in the full stage of AIDS. The mean follow-up was
14.4 months. RESULTS: A total of 25 cases of Pneumocystis carinii
pneumonia was observed (3.83/year): in the primary prophylaxis group 18
(3.25%/year), in the secondary prophylaxis group seven (6.8%/year). By
introducing the loading dose (one inhalation per day for five
consecutive days for patients with CD4 cell counts below 150 c/mcl) we
reduced the percentage of early manifestations within the first three
months from 61% to 14%. No extrapulmonary Pneumocystis carinii
manifestation was observed. CONCLUSION: This study supports the efficacy
of pentamidine aerosol prophylaxis of primary and secondary Pneumocystis
carinii pneumonia.
DE Administration, Inhalation Adult Aerosols AIDS-Related Opportunistic
Infections/*PREVENTION & CONTROL English Abstract Female Follow-Up
Studies Human Male Middle Age Pentamidine/*ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS Pneumonia, Pneumocystis carinii/*PREVENTION &
CONTROL Recurrence Retrospective Studies JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).